drug

tildrakizumab-asmn

1 story · latest Oct 29, 2026

Follow tildrakizumab-asmn. Every new filing, FDA action, and trial change, in your feed and a morning email, each linked to its source.

Follow free for 14 daysNo card.

Status: FDA approved Mar 2018 · BLA761067
Brand: Ilumya

Relationships

Developed by Sun Pharmaceutical Industries

Timeline

FDA approves efficacy supplement for Sun Pharma's Ilumya

Oct 29Regulatory decisionSun Pharmaceutical Industries tildrakizumab-asmn

Biotech intelligence from primary sources. Every story is an original summary of a public record, linked to its source. Not investment advice.

Terms Privacy hello@readthrough.news

readthrough is a product of JAMN Ventures, LLC.